BeiGene Launches U.S. Biologics Manufacturing and R&D Facility

BeiGene Launches U.S. Biologics Manufacturing and R&D Facility

By, Admin 25 July 2024

BeiGene Launches U.S. Biologics Manufacturing and R&D Facility, Advancing Global Expansion to Serve More Patients

Overview

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, has launched its flagship U.S. facility at the Princeton West Innovation Campus in Hopewell, N.J. This advanced site features cutting-edge biologics manufacturing capabilities and a clinical research and development center, further enhancing BeiGene’s innovative approach in oncology. With over 30 molecules at various stages of clinical and commercial development, the 42-acre facility is designed to scale production of new cancer treatments to meet patient needs now and in the future.

Words from the CEO: BeiGene

  • BeiGene’s global expansion is significantly supported by the addition of this new facility at the Princeton West Innovation Campus, which enhances our manufacturing and clinical development capabilities. This aligns with our strategy of leveraging speed, efficiency, and technology to deliver quality medicines faster,"" stated John V. Oyler, Co-Founder, Chairman, and CEO of BeiGene. 
  • We are excited to join New Jersey’s vibrant biopharmaceutical community, known for its rich R&D and manufacturing talent. We aim to strengthen regional partnerships as we advance our robust pipeline of next-generation hematology and solid tumor treatments, establishing ourselves as a leading global oncology innovator.

Future Investment

  • This $800 million investment is the culmination of a three-year project to expand BeiGene’s U.S. manufacturing and R&D footprint, creating hundreds of high-tech jobs at the site by the end of 2025. 
  • New Jersey, a global leader in biopharmaceutical manufacturing and R&D, is home to nine of the top ten R&D companies. 
  • Its robust biopharmaceutical workforce and strategic infrastructure offer access to major markets worldwide.

From the Governor: New Jersey

  • I am thrilled by BeiGene’s contribution to our state’s thriving biopharmaceutical sector,"" said Governor Phil Murphy. 
  • The opening of BeiGene’s flagship campus underscores our commitment to fostering innovation and creating high-tech jobs. This significant investment reaffirms New Jersey’s role as a global leader in pharmaceutical manufacturing, research, and development. We support BeiGene’s mission to develop affordable and accessible cancer treatments.

About Pharmaceutical Manufacturing Facility

  • The 400,000-square-foot facility is dedicated to commercial-stage biologic pharmaceutical manufacturing, with room for future expansion. 
  • It complements BeiGene’s late-stage research and clinical development capabilities, supporting the company's rise in global oncology leadership. 
  • BeiGene’s pipeline targets 80% of the world’s cancers with innovative treatments, including targeted degraders, antibody-drug conjugates (ADCs), monoclonal antibodies, and traditional small molecules. 
  • This new facility enhances BeiGene’s capacity to produce at scale, reduce costs, ensure supply chain resilience, and adapt to the latest treatment modalities.

Statement from the Hopewell Township Mayor

  • Welcome, BeiGene, to Hopewell Township. This cutting-edge pharmaceutical facility represents a significant investment in our community. The life-saving medicines produced here will advance global cancer treatment, create high-tech jobs, and boost our local economy,"" said Hopewell Township Mayor Courtney Peters-Manning. 
  • We look forward to BeiGene’s continued success in our township.

About BeiGene

  • BeiGene is committed to sustainability, recognizing the link between human health and environmental health. 
  • The facility incorporates sustainable features, including a heating and cooling system that uses recycled wastewater and solar-ready infrastructure.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!